Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane).
about
The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretationAntimitotic drugs in the treatment of cancerIs the Evaluation of Quality of Life in NSCLC Trials Important? Are the Results to be Trusted?Chemotherapy-induced peripheral neurotoxicity: a critical analysisChemotherapy research for metastatic prostate cancerTaxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review.Are the data on quality of life and patient reported outcomes from clinical trials of metastatic non-small-cell lung cancer important?Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel.Weekly nanoparticle albumin-bound paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinomaThe influence of chemotherapy-induced neurotoxicity on psychological distress and sleep disturbance in cancer patients.Quality-of-life evaluation for advanced non-small-cell lung cancer: a comparison between vinorelbine plus gemcitabine followed by docetaxel versus paclitaxel plus carboplatin regimens in a randomized trial: Japan Multinational Trial Organization LC0Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey.Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01.Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer.Reliability of the Brazilian version of the Functional Assessment of Cancer Therapy-Lung (FACT-L) and the FACT-Lung Symptom Index (FLSI).A highly tumor-targeted nanoparticle of podophyllotoxin penetrated tumor core and regressed multidrug resistant tumors.Quality of life in patients receiving treatment for gynecologic malignancies: special considerations for patient care.Subgroup effects in a randomised trial of different types and doses of exercise during breast cancer chemotherapyGender differences in paclitaxel-induced neuropathic pain behavior and analgesic response in rats.Objective evaluation of the alleviating effects of Goshajinkigan on peripheral neuropathy induced by paclitaxel/carboplatin therapy: A multicenter collaborative studyThe Breast Cancer Quality of Care Study (BQUAL): a multi-center study to determine causes for noncompliance with breast cancer adjuvant therapy.Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities.Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell tumor: clinical outcome and quality of life in long-term survivors.Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy.Orofacial pain in cancer: part I--mechanisms.Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial - CALGB/alliance 170601The Pathways Study: a prospective study of breast cancer survivorship within Kaiser Permanente Northern CaliforniaRandomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapyQuality of life and adjuvant systemic therapy for early-stage breast cancer.A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinomaRandomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer.Intratumoral delivery of Paclitaxel in solid tumor from biodegradable hyaluronan nanoparticle formulations.Development of a novel location-based assessment of sensory symptoms in cancer patients: preliminary reliability and validity assessment.Reliability and validity of the Functional Assessment of Chronic Illness Therapy-Palliative care (FACIT-Pal) scale.Delayed emotional recovery after taxane-based chemotherapy.Chemotherapy-induced peripheral neuropathy: prevention and treatment.Current status and future perspectives of patient-reported outcome research in clinical trials for patients with breast cancer in Japan.Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review.Chemotherapy-induced polyneuropathy: major agents and assessment by questionnaires.What about Alice? Peripheral neuropathy from taxane-containing treatment for advanced nonsmall cell lung cancer.
P2860
Q24807048-E21E3B8A-A161-4BDA-A160-4FD87B021283Q26777317-4340AB84-D628-48D8-A74F-E8B285F43408Q27006021-99862254-2174-4F89-9D2C-4013DF4CF1A2Q27010318-E665FF4A-EDEA-4155-80DB-D8C98551C898Q28071468-7BA37B59-E489-4BDD-9C3A-5AB9D8EF1CFAQ30251429-EDB0CBD6-47F3-4960-A720-B8270CCBFC24Q30830928-A1D75B33-2D5A-42BF-87D6-B0777B299FDCQ33423320-FB46B5D1-F556-474F-9105-220ED2ED9E00Q33435812-DF21BE28-C099-479F-AEAC-7BB0E3E28A00Q33982653-5F1D99AA-1138-4397-B9A5-AFA25E87A023Q33995141-BE5EEF09-3DFD-4FE8-B320-8F9D8850EEAFQ34035471-0CC2A999-B4B1-462D-A10A-D74804E01690Q34039871-4D3021D4-BFFA-4972-B276-68910FF38242Q34458581-CE74F3C9-6BC9-4228-831F-09379F801BFCQ34486936-438055C4-ED31-42F0-8679-6870C7E9464BQ35232504-AFAFA249-EB68-4686-9406-2BCE9E5EDF30Q35648863-FE201055-FBB5-433D-82AF-22F1CDF3A353Q35678060-02EB1B94-336D-4814-BC23-474335ADFE47Q35738165-888D707C-9B1B-4C28-9C61-7731873C848CQ36225009-0CCA8C82-9BEB-47F5-9C00-679958AC8722Q36459112-AE4095AF-AFDB-468A-9A9C-0DE9FFC3981EQ36463131-7A35EC21-3FA9-4EA3-839D-83DBF7C8C554Q36565476-4F83F4E2-2045-4335-9990-A533AAA6B167Q36775383-B386C84D-1205-4B0B-BC40-A49ABC55A781Q36831523-376E2028-4CC7-40FD-8371-A4C5A0FFC0A9Q36932675-DA0C7F04-E3E6-47E3-AD5A-041013FB2A89Q36968612-369D75DE-BA62-4812-99A7-2DE11867A68EQ36977059-656EC2DE-708E-4AFC-B5A3-6E9EAF42BB29Q37008863-0486B447-43BD-4659-A8F8-2F33B970AC34Q37023744-25238B20-AB8B-41E8-9E55-974C4E270A2FQ37046151-5259A2A6-04E5-4ECC-9091-68E11EE95848Q37213277-45D7CE1F-3D99-42BA-857D-366782BD6078Q37231992-5FD4E6E3-226D-474F-934F-D8776BC11964Q37352322-A3E7BD5A-3104-4437-BE47-06EB7E65BA38Q37352503-E9304AC8-E336-4A81-A26A-8E936DE5C4CEQ37911252-87470861-6784-4B2B-B9D6-DDB85E9D6930Q38008568-C9DAAF49-67C4-4C4B-BA1B-0B4565DEDD3EQ38208769-4D62B885-1099-45E5-90DE-8A17E6986509Q38209390-EBE133A7-3F51-4D6E-8ADA-58C2D44991B7Q38222174-4DACBDF1-7B77-4177-8CA9-B7EB73397FD0
P2860
Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane).
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Measuring the side effects of ...... therapy-taxane (FACT-taxane).
@en
Measuring the side effects of ...... sment of cancer therapy-taxane
@nl
type
label
Measuring the side effects of ...... therapy-taxane (FACT-taxane).
@en
Measuring the side effects of ...... sment of cancer therapy-taxane
@nl
prefLabel
Measuring the side effects of ...... therapy-taxane (FACT-taxane).
@en
Measuring the side effects of ...... sment of cancer therapy-taxane
@nl
P2093
P356
P1433
P1476
Measuring the side effects of ...... therapy-taxane (FACT-taxane).
@en
P2093
Amy Peterman
Kimberly Webster
Mark A Socinski
Stacie Hudgens
P304
P356
10.1002/CNCR.11578
P407
P50
P577
2003-08-01T00:00:00Z